AL16ALA-SOD2 polymorphism predicts recurrence risk of breast cancer in patients treated with adjuvant tamoxifen

AL16ALA-SOD2 polymorphism predicts recurrence risk of breast cancer in patients treated with adjuvant tamoxifen

Introduction: Approximately 30% of patients with hormone receptor-positive breast cancer show resistance to tamoxifen, which may result in local or distant recurrence. Based on previous evidence, it can be inferred that tamoxifen sensitivity is influenced by an oxidative genetic imbalance. Objective...

Full description

Bibliographic Details
Main Authors: Maiquidieli Dal Berto, Laura Martin Manfroi, Aniúsca Vieira dos Santos, Giovana Tavares dos Santos, Gabriela Krüger da Costa, Camila Macedo Boaro, Péttala Rigon, Rafael José Vargas Alves, Claudia Giuliano Bica
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Advances in Cancer Biology - Metastasis
Subjects:
Breast cancer
Relapse
Val16Ala-SOD2 polymorphism
Tamoxifen
Online Access:http://www.sciencedirect.com/science/article/pii/S2667394023000229

Internet

http://www.sciencedirect.com/science/article/pii/S2667394023000229

Similar Items